Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iafrate

Showing results (531-540 of 580) with videos related to

Pageof 58
Sort By:
The New England Journal of Medicine|July 12, 2023
BRAF-MEK Inhibition in Newly Diagnosed Papillary CraniopharyngiomasPriscilla K Brastianos, Erin Twohy, Susan Geyer, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Nature Communications|March 12, 2015
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerMatthew J Niederst, Lecia V Sequist, John T Poirier, et al.
Cancer Discovery|December 31, 2016
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive CholangiocarcinomaLipika Goyal, Supriya K Saha, Leah Y Liu, et al.
Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Cancer Cell|August 15, 2018
Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell CarcinomaRaj K Gopal, Kirsten Kübler, Sarah E Calvo, et al.
Journal for Immunotherapy of Cancer|April 20, 2025
Reversible downregulation of HLA class I in adenoid cystic carcinomaAnnie Li, Bianca L Gonda, Elizabeth M Codd, et al.
Journal of the National Cancer Institute|April 11, 2023
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinomaKristen Spencer, Leontios Pappas, Islam Baiev, et al.
JCO Precision Oncology|August 10, 2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With CholangiocarcinomaLeontios Pappas, Islam Baiev, Stephanie Reyes, et al.
Pageof 58

Showing results (531-540 of 580) with videos related to

Sort By:
Pageof 58
The New England Journal of Medicine|July 12, 2023
BRAF-MEK Inhibition in Newly Diagnosed Papillary CraniopharyngiomasPriscilla K Brastianos, Erin Twohy, Susan Geyer, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Nature Communications|March 12, 2015
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerMatthew J Niederst, Lecia V Sequist, John T Poirier, et al.
Cancer Discovery|December 31, 2016
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive CholangiocarcinomaLipika Goyal, Supriya K Saha, Leah Y Liu, et al.
Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Cancer Cell|August 15, 2018
Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell CarcinomaRaj K Gopal, Kirsten Kübler, Sarah E Calvo, et al.
Journal for Immunotherapy of Cancer|April 20, 2025
Reversible downregulation of HLA class I in adenoid cystic carcinomaAnnie Li, Bianca L Gonda, Elizabeth M Codd, et al.
Journal of the National Cancer Institute|April 11, 2023
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinomaKristen Spencer, Leontios Pappas, Islam Baiev, et al.
JCO Precision Oncology|August 10, 2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With CholangiocarcinomaLeontios Pappas, Islam Baiev, Stephanie Reyes, et al.
Pageof 58